Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: A retrospective study from the EBMT

L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. De Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D. VallisaE. Zuffa, A. Sureda, P. Dreger

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

Original languageEnglish
Pages (from-to)212-218
Number of pages7
JournalBone Marrow Transplantation
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Thiotepa
Stem Cell Transplantation
Lymphoma
Retrospective Studies
Melphalan
Cytarabine
Etoposide
Follicular Lymphoma
Therapeutics
Hodgkin Disease
Central Nervous System
Carmustine
Survival
Lymphoma, Large B-Cell, Diffuse
Registries
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma : A retrospective study from the EBMT. / Sellner, L.; Boumendil, A.; Finel, H.; Choquet, S.; De Rosa, G.; Falzetti, F.; Scime, R.; Kobbe, G.; Ferrara, F.; Delmer, A.; Sayer, H.; Amorim, S.; Bouabdallah, R.; Finke, J.; Salles, G.; Yakoub-Agha, I.; Faber, E.; Nicolas-Virelizier, E.; Facchini, L.; Vallisa, D.; Zuffa, E.; Sureda, A.; Dreger, P.

In: Bone Marrow Transplantation, Vol. 51, No. 2, 01.02.2016, p. 212-218.

Research output: Contribution to journalArticle

Sellner, L, Boumendil, A, Finel, H, Choquet, S, De Rosa, G, Falzetti, F, Scime, R, Kobbe, G, Ferrara, F, Delmer, A, Sayer, H, Amorim, S, Bouabdallah, R, Finke, J, Salles, G, Yakoub-Agha, I, Faber, E, Nicolas-Virelizier, E, Facchini, L, Vallisa, D, Zuffa, E, Sureda, A & Dreger, P 2016, 'Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: A retrospective study from the EBMT', Bone Marrow Transplantation, vol. 51, no. 2, pp. 212-218. https://doi.org/10.1038/bmt.2015.273
Sellner, L. ; Boumendil, A. ; Finel, H. ; Choquet, S. ; De Rosa, G. ; Falzetti, F. ; Scime, R. ; Kobbe, G. ; Ferrara, F. ; Delmer, A. ; Sayer, H. ; Amorim, S. ; Bouabdallah, R. ; Finke, J. ; Salles, G. ; Yakoub-Agha, I. ; Faber, E. ; Nicolas-Virelizier, E. ; Facchini, L. ; Vallisa, D. ; Zuffa, E. ; Sureda, A. ; Dreger, P. / Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma : A retrospective study from the EBMT. In: Bone Marrow Transplantation. 2016 ; Vol. 51, No. 2. pp. 212-218.
@article{70014698fa8c4ef39b9f52026afb7a1a,
title = "Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: A retrospective study from the EBMT",
abstract = "Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.",
author = "L. Sellner and A. Boumendil and H. Finel and S. Choquet and {De Rosa}, G. and F. Falzetti and R. Scime and G. Kobbe and F. Ferrara and A. Delmer and H. Sayer and S. Amorim and R. Bouabdallah and J. Finke and G. Salles and I. Yakoub-Agha and E. Faber and E. Nicolas-Virelizier and L. Facchini and D. Vallisa and E. Zuffa and A. Sureda and P. Dreger",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/bmt.2015.273",
language = "English",
volume = "51",
pages = "212--218",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma

T2 - A retrospective study from the EBMT

AU - Sellner, L.

AU - Boumendil, A.

AU - Finel, H.

AU - Choquet, S.

AU - De Rosa, G.

AU - Falzetti, F.

AU - Scime, R.

AU - Kobbe, G.

AU - Ferrara, F.

AU - Delmer, A.

AU - Sayer, H.

AU - Amorim, S.

AU - Bouabdallah, R.

AU - Finke, J.

AU - Salles, G.

AU - Yakoub-Agha, I.

AU - Faber, E.

AU - Nicolas-Virelizier, E.

AU - Facchini, L.

AU - Vallisa, D.

AU - Zuffa, E.

AU - Sureda, A.

AU - Dreger, P.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

AB - Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84956914609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956914609&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.273

DO - 10.1038/bmt.2015.273

M3 - Article

AN - SCOPUS:84956914609

VL - 51

SP - 212

EP - 218

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -